noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Blue Cross and Blue Shield of[...]

Blue Cross and Blue Shield of Texas Launches Edge Plans Powered by Easify
The Office of the Governor of the[...]

Governor Lamont Signs Law Increasing Job Benefits for State and Local[...]
State of Delaware Department of[...]

TRAFFIC ALERT - New Castle County - Tree Removal in Several Spots

Healthcare

Lake Street Capital Markets LLC

06/11/2026 | Press release | Distributed by Public on 06/11/2026 08:08

Kazia Therapeutics Limited (KZIA) - Initiation of Coverage

Lake Street Capital Markets Analyst, Chad Messer, Ph.D., initiated coverage of Kazia Therapeutics, Limited with a BUY rating and price target of $32 (KZIA-$32). Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel.

‍

Want to stay up-to-date with the latest at Lake Street? Subscribe to our mailing list!

NameEmail Address

Thanks for joining our mailing list.

Oops! Something went wrong while submitting the form.

Attachment

Lake Street Capital Markets LLC published this content on June 11, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 11, 2026 at 14:08 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format